Search results for: Real World Evidence (RWE)
Filter search results
Professor Dame Sally Davies: Ten Years of the NIHR: Achievements and Challenges for the Next Decade
15 June 2017
…the use of “Big Data” and gathering “real world evidence”; discussed how to demonstrate the value, in terms of both health and wealth, of major NHS investment in R&D; explored…
What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?
9 July 2018
…a sample of patients. Collecting real-world data on the treatment outcomes achieved by patients will increasingly be required, again, at least for a sample of patients. However, proxies for, or…
The Value of International Volunteers’ Experience to the NHS
24 April 2019
…volunteers, which have been identified as relevant from an NHS perspective, are linked to three key areas in a multisector analytical framework used by the World Bank to evaluate labour…
OHE at the 2019 Health Technology Assessment International (HTAi) Annual Meeting
7 June 2019
…of value; flexible, value-based, indication-specific pricing of complementary diagnostic tests and medicines; ongoing real-world evidence generation; and appropriate methods to divide and reward value among complementary diagnostic tests and medicines….
OHE has an Opening for an Industrial Economist
20 November 2019
…and competition in the health care and the pharmaceutical markets Health econometrics and real-world evidence Applications must be received by close of business on Wednesday 4th December 2019. Interviews for shortlisted candidates will…
Opportunity Cost in Health Care: a Favourite Research Topic for OHE
23 November 2021
…investing in programme A – if it exhausts our budget – is what we could have achieved with programme B, which could not be provided. But the reality is not…
Scarce Resources in Health Care
2 January 1979
…needs, and that, then, these resources could be fairly allocated to those requiring them. Unfortunately, well intentioned as these attempts have been, the reality is that the problem is much…
Narrowing the Gap between provision and need for medicines in developing countries
1 February 2000
…therefore not a priority for the investors in pharmaceutical R&D. In 1992, of the $55.8 billion invested in health care world-wide, only an estimated $2.4 billion or 4 percent were…
Ten Years of the NIHR: Achievements and Challenges for the Next Decade
1 June 2017
…gathering “real world evidence”; discusses how to demonstrate the value, in terms of both health and wealth, of major NHS investment in R&D; explores how to keep the UK punching…